Because P-gp antagonists were shown to replace D-threo-PDMP in the SACLAC regimen, we conclude that targeting P-gp, as opposed to GCS specifically, may be a more favorable route for limiting ceramide glycosylation to enhance “the ceramide effect” in treatment of drug-resistant cancer. Here, PGP is linked to cancer.